Unlocking the next generation of complement therapies We are focused on stopping C1q, the initiating molecule of the classical complement pathway, at the start to treat devastating autoimmune, neurodegenerative, and ophthalmic diseases of the body, brain and eye. Our science We target C1q to block all damaging components of the immune system’s classical complement pathway. Learn more Our pipeline […]
Total raised: $78M
Founded date: 2011
Investors 3
| Date | Name | Website |
| 06.07.2021 | New Enterp... | nea.com |
| 17.07.2020 | Logos Capi... | logoscapit... |
| - | Bain Capit... | baincapita... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 23.06.2016 | Series B | $44M | New Enterp... |
| 15.12.2014 | Series A | $34M | - |
Mentions in press and media 12
| Date | Title | Description |
| 25.06.2024 | Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 PNS Annual Meeting | ANX005-Treated Patients Demonstrated Faster and More Complete Recovery from Week 1 through Week 26 on Primary and Multiple Pre-Specified Endpoints Two and a Half Times More ANX005-Treated Patients Returned to a Normal / Pre-Disease State of... |
| 13.11.2023 | Annexon Reports Significant Progress with its Priority Programs and Third Quarter 2023 Financial Results | Company Prioritizes Greatest Near-term Value-Driving Programs: ANX005 for Guillain-Barré Syndrome (GBS), ANX007 for Geographic Atrophy (GA) and First-in-Kind Complement Small Molecule, ANX1502 ANX005 Phase 3 Pivotal Data in GBS On Track for... |
| 08.01.2023 | Annexon Highlights Strategic Focus to Advance Four Flagship Complement Programs through Late-Stage Development and Progress Across Three Therapeutic Franchises | Mid-stage and Pivotal Trials of ANX005, ANX007 and ANX1502 Poised to Achieve Numerous Catalysts in Multiple Disease Indications Well-Capitalized with Operating Runway into 2025 Company to Present Pipeline Updates at 41st Annual J.P. Morgan ... |
| 02.07.2020 | Annexon grabs $100M from a host of top VC firms for complement therapies | Annexon Biosciences has grabbed a healthy $100 million round to take its clinical work closer to the finishing line as it tees up shots on multiple targets. Sponsored by Agilent Technologies How would you like to win free bench space at Lab... |
| 19.12.2018 | Annexon Biosciences Closes $75M in Series C | SOUTH SAN FRANCISCO, CA, Clinical stage biopharmaceutical company announced that it has closed a $75 million Series C financing. >> Click here for more funding data on Annexon Biosciences >> To export Annexon Biosciences fun... |
| 23.06.2016 | NEA leads $44M round to get Stanford neurodegenerative spinout Annexon into the clinic | Annexon Biosciences has snagged a major new VC to help back its ambitious, early neurodegenerative research. New Enterprise Associates has come in to lead a $44 million Series B round for the startup, which is slated to get the startup thro... |
| 23.06.2016 | NEA Leads $44M Series B for Annexon Biosciences | SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Annexon Biosciences, a biopharmaceutical company pioneering the development of classical complement pathway inhibitors to treat neurodegenerative disorders, today announced that it has closed a ... |
| 23.06.2016 | Novartis Venture Fund Joins $44M Series B for Annexon Biosciences | SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Annexon Biosciences, a biopharmaceutical company pioneering the development of classical complement pathway inhibitors to treat neurodegenerative disorders, today announced that it has closed a ... |
| 23.06.2016 | Biopharmaceutical Company Annexon Biosciences Closes $44M Series B Funding | Annexon Biosciences, a South San Francisco, CA-based biopharmaceutical company developing classical complement pathway inhibitors to treat neurodegenerative disorders, closed $44m Series B financing round. The round was led by new investor ... |
| 31.03.2016 | New insight into Alzheimer’s suggests potential path to treatment | An immune process implicated earlier this year in schizophrenia may also cause the devastating brain damage of Alzheimer’s disease, a surprising convergence that suggests the body’s defense system is responsible for two of the cruelest brai... |
Show more